KINAXO Announces Agreement with Johnson & Johnson Pharmaceutical Research & Development

15-Jan-2007

Kinaxo Biotechnologies GmbH announced that it has entered an agreement with Johnson & Johnson Pharmaceutical Research & Development (J&JPRD), a division of Janssen Pharmaceutica. Under the agreement, KINAXO will use the KinaTorTM technology to perform target selectivity analyses for selected J&JPRD small molecule compounds.

The KinaTorTM technology uses immobilized small molecule inhibitors to detect their protein binding partners in biological samples. Small molecule-protein interactions are identified by a combination of sophisticated affinity-based separation procedures and sensitive mass spectrometry. The KinaTorTM provides tailor-made solutions for various problems in drug development, such as the identification of previously unknown disease-relevant targets as well as off-target related toxicities.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic World Spectroscopy

Investigation with spectroscopy gives us unique insights into the composition and structure of materials. From UV-Vis spectroscopy to infrared and Raman spectroscopy to fluorescence and atomic absorption spectroscopy, spectroscopy offers us a wide range of analytical techniques to precisely characterize substances. Immerse yourself in the fascinating world of spectroscopy!

15+ products
10+ whitepaper
15+ brochures
View topic world

Topic World Spectroscopy

Investigation with spectroscopy gives us unique insights into the composition and structure of materials. From UV-Vis spectroscopy to infrared and Raman spectroscopy to fluorescence and atomic absorption spectroscopy, spectroscopy offers us a wide range of analytical techniques to precisely characterize substances. Immerse yourself in the fascinating world of spectroscopy!

15+ products
10+ whitepaper
15+ brochures